Associated Papers
Role of common host genome variants in Childhood Acute Lymphoblastic Leukemia.
Mikkelsen T et al.
Leukemia, 2026
Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate.
Cui J et al.
Seminars in Arthritis and Rheumatism, 2022
Genetic Predictors for Sinusoidal Obstruction Syndrome-A Systematic Review.
Waespe N et al.
Journal of Personalized Medicine, 2021
Effect of Polymorphisms of ABCB1 and MTHFR on Methotrexate-Related Toxicities in Adults With Hematological Malignancies.
Han J et al.
Frontiers in Oncology, 2021
Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response.
Mikhaylenko DS et al.
International Journal of Molecular Sciences, 2020
Pharmacogenomics, biomarker network, and allele frequencies in colorectal cancer.
López-Cortés A et al.
The Pharmacogenomics Journal, 2020
The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.
Rudin S et al.
Genomics, Proteomics & Bioinformatics, 2017
The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy.
Tarnowski M et al.
Expert Opinion on Drug Metabolism & Toxicology, 2016
Germline oncopharmacogenetics, a promising field in cancer therapy.
Pesenti C et al.
Cellular Oncology (dordrecht, Netherlands), 2015
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies.
Dulucq S et al.
Expert Opinion on Drug Metabolism & Toxicology, 2014
Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia.
Lu Y et al.
British Journal of Cancer, 2014
Lack of association between polymorphisms in genes MTHFR and MDR1 with risk of childhood acute lymphoblastic leukemia.
Kreile M et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2014
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review).
Martino A et al.
International Journal of Oncology, 2012
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
Cecchin E et al.
The Pharmacogenomics Journal, 2011
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.
Rocha V et al.
Leukemia, 2009
Pharmacogenetics in chemotherapy of colorectal cancer.
Henriette Tanja L et al.
Best Practice & Research. Clinical Gastroenterology, 2009
Pharmacogenetics of acute lymphoblastic leukemia treatment response.
Cunningham L et al.
Expert Opinion on Pharmacotherapy, 2007
Pharmacogenetics for individualized cancer chemotherapy.
Efferth T et al.
Pharmacology & Therapeutics, 2005
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Toffoli G et al.
Journal of Chemotherapy (florence, Italy), 2004
Pharmacogenetics of disease-modifying anti-rheumatic drugs.
Tanaka E et al.
Best Practice & Research. Clinical Rheumatology, 2004